Synthetic Biology Startup Funding 2025-2026
In our synthetic biology market deck, you will find everything you need to understand the market
SUMMARY
This report analyzes every publicly disclosed equity round raised by pure-play synthetic biology companies between August 2025 and July 2026, a 12-month window covering every geography. We only kept rounds of $300K or more, and excluded conventional biotech, basic GMOs, traditional fermentation, grants, debt, IPOs, acquisitions, and non-separable grant-blended rounds.
Over this period, fundraising in the synthetic biology market was small by deal count but large by dollars. The dataset includes 19 disclosed deals and $1.01B raised across 19 unique companies.
Capital in the synthetic biology market is highly concentrated. The top deal alone represents 42.9% of total funding, the top 3 deals reach 68.4%, and the top 10 deals reach 92.5%.
NewLimit changes the whole funding picture. Without its $435M Series C, disclosed capital falls from $1.01B to $579M.
The median round size is a better guide than the average. The median disclosed round is $19M, while the average is $53.4M because a few large rounds pull the number up.
Deal flow was modest in the synthetic biology market. The dataset averages 1.58 deals per month, with a median of 1 deal per month.
Synthetic Biology Therapeutics dominates capital. The category raised $664.1M, or 65.5% of total disclosed funding, from only 4 deals.
Synbio Design Software, Engineered Microbes, and Synthetic Biology Therapeutics are tied by deal count. Each category produced 4 deals, but their dollar outcomes were very different.
The synthetic biology market is late-stage-heavy by capital but Series A-heavy by activity. Series C rounds captured 50.2% of dollars, while Series A rounds accounted for 42.1% of deals.
North America dominates the market by capital depth. It captured $849.4M, or 83.8% of total disclosed funding, from 8 deals.
Repeat investors were rare. SOSV was the only clearly identifiable investor with more than one qualifying disclosed deal, appearing in Scindo, Cauldron Ferm, and Fermeate.
This market map, featured in our synthetic biology market deck, highlights top companies and startups in the synthetic biology market
What are all the funding deals in the synthetic biology market from August 2025 to July 2026?
The table below lists every disclosed equity round raised by pure-play synthetic biology companies between August 2025 and July 2026. We count as “pure-play” synthetic biology companies those where more than 80% of activity relies on engineered biological systems, designed DNA, genetic circuits, engineered organisms, or specialized tools that enable those workflows.
Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors, and the announcement source. For a wider view of the opportunity, we cover it in our Synthetic Biology market report.
| Company | What they do | Category | Date | Stage | Deal size | Region | Main investors | Source |
|---|---|---|---|---|---|---|---|---|
| Strand Therapeutics | Programmable mRNA therapeutics designed to express therapeutic payloads in targeted cells, initially for oncology | Synthetic Biology Therapeutics | Aug 2025 | Series B | $153M | North America | Not specified in dataset | Business Wire |
| Scindo | AI-enabled enzyme discovery and design platform for bio-based ingredients and sustainable chemistry | Synbio Design Software | Sep 2025 | Seed | $5.4M | Europe | SOSV | AgFunderNews |
| Ansa Biotechnologies | Enzymatic DNA synthesis services, including long clonal DNA, to help scientists build designed biological systems | Biofoundry Platforms | Oct 2025 | Series B | $54.4M | North America | Not specified in dataset | Ansa Biotechnologies |
| Biocentis | Programmable genetic insect-control systems for health, agriculture, and biodiversity applications | Engineered Microbes | Nov 2025 | Seed | $19M | Europe | Not specified in dataset | Business Wire |
| Profluent | Frontier AI models for programmable biology, including genome editors, antibodies, and enzymes | Synbio Design Software | Nov 2025 | Series A | $106M | North America | Not specified in dataset | Business Wire |
| Cellarim Labs | Cell-free biomanufacturing for high-purity beauty and personal-care ingredients | Synbio Materials Platforms | Dec 2025 | Seed | $0.72M | Asia-Pacific | 3i Partners | StartupTalky |
| bit.bio | Human cell programming using opti-ox technology to produce defined cells for research and drug discovery | Biofoundry Platforms | Jan 2026 | Series C | $50M | Europe | Not specified in dataset | bit.bio |
| Think Bioscience | Uses synthetic biology, enzymology, protein biophysics, computational chemistry, and medicinal chemistry to unlock difficult drug targets | Synthetic Biology Therapeutics | Jan 2026 | Series A | $55M | North America | Not specified in dataset | PR Newswire |
| Octarine Bio | Precision-fermented natural pigments for food, textiles, and personal care through a sustainable color platform | Synbio Materials Platforms | Jan 2026 | Series A | $5.8M | Europe | Not specified in dataset | EU-Startups |
| Antheia | Advanced biosynthesis and engineered biology to manufacture complex pharmaceutical ingredients | Engineered Microbes | Jan 2026 | Series C | $24M | North America | Not specified in dataset | Antheia |
| baCta | AI-powered strain-engineering and precision-fermentation systems using microorganisms as programmable molecular factories | Engineered Microbes | Mar 2026 | Seed | $8.3M | Europe | Not specified in dataset | AgFunderNews |
| Cauldron Ferm | Continuous hyper-fermentation infrastructure to make industrial-scale biomanufacturing cheaper and more scalable | Biofoundry Platforms | Mar 2026 | Series A | $13.25M | Asia-Pacific | SOSV | Business Wire |
| Epoch Biodesign | AI and synthetic biology to design enzymes for recycling plastic and textile waste, especially nylon 6,6 | Synbio Materials Platforms | Mar 2026 | Unknown | $12M | Europe | Not specified in dataset | EU-Startups |
| Scala Biodesign | ScalaOS, an AI-driven protein-design platform for biologics, enzymes, antibodies, vaccines, and industrial proteins | Synbio Design Software | Mar 2026 | Series A | $16M | Middle East | Not specified in dataset | BioSpace |
| Fermeate | Optogenetic control of gene expression to improve productivity and economics in industrial precision fermentation | Engineered Microbes | Apr 2026 | Seed | $2M | North America | SOSV | Business Wire |
| Pumpkinseed | Nanophotonic protein-sequencing platform to generate functional proteomic datasets for biopharma, biosecurity, and AI biology | Synbio Design Software | May 2026 | Series A | $20M | North America | Not specified in dataset | Pumpkinseed |
| StrainX Bioworks | Precision-fermentation and synthetic-biology platform for high-value nutritional and flavor ingredients | Synbio Food Platforms | May 2026 | Series A | $13M | Asia-Pacific | Not specified in dataset | AgFunderNews |
| NewLimit | AI-driven epigenetic reprogramming medicines using transcription-factor combinations to restore youthful cellular function | Synthetic Biology Therapeutics | Jun 2026 | Series C | $435M | North America | Not specified in dataset | FinSMEs |
| Telum Therapeutics | Metagenomic datasets, synthetic biology, and generative AI to develop protein-based antimicrobial therapeutics | Synthetic Biology Therapeutics | Jul 2026 | Series A | $21.1M | Europe | Not specified in dataset | Telum Therapeutics |
In our synthetic biology market deck, we identify pain points entrepreneurs should prioritize
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this synthetic biology funding tracker by reviewing every publicly disclosed equity round raised by pure-play synthetic biology companies between August 2025 and July 2026. A company counts as pure-play when more than 80% of its activity is dedicated to tools, platforms, or products that rely on engineering biological systems using designed DNA, genetic circuits, engineered organisms, or closely related synthetic biology workflows.
We applied four filters to build the dataset. First, we only included equity rounds, so grants, debt, IPOs, acquisitions, and non-separable grant-blended rounds are excluded. Second, we only counted rounds of $300K or more. Third, we only kept pure-play synthetic biology companies. And fourth, every entry had to be confirmed by a direct company announcement, a press release, or a tier-1 or strong sector media report, with the source URL preserved for every row.
The final dataset contains 19 disclosed deals across 19 unique companies, and every average, median, share, and concentration ratio is computed on that disclosed sample. Privately raised rounds that were never publicly announced are necessarily missing, which is a known limitation of any public-only synthetic biology funding tracker.
How active has fundraising been in the synthetic biology market?
As of July 2026, fundraising in the synthetic biology market has been selective rather than broad. Over the past 12 months, companies raised 19 disclosed equity rounds and $1.01B combined, which works out to 1.58 deals per month.
The monthly activity pattern is modest. Median deal flow was 1 deal per month, and February 2026 had no qualifying disclosed round in the dataset.
Capital flow tells a more volatile story. The average month produced $84.5M of disclosed funding, but the median month produced only $41.3M, showing how strongly outliers shape the synthetic biology market.
June 2026 was the largest month by dollars because of NewLimit alone. January and March 2026 were the most active months by deal count, with 4 deals each.
If you’re interested in knowing more about the top startups in this industry, check our market report covering synthetic biology companies.
How concentrated has fundraising been in the synthetic biology market?
As of July 2026, fundraising in the synthetic biology market has been highly concentrated at the top. Over the past 12 months, the largest deal accounts for 42.9% of all capital raised, the top 3 deals reach 68.4%, and the top 5 reach 79.2%.
The top deal is NewLimit’s $435M Series C. That one round is larger than the combined disclosed funding of every company outside the top 5.
The top 10 deals account for 92.5% of disclosed capital. This means the bottom 9 deals collectively represent only 7.5% of funding in the synthetic biology market.
This concentration changes how the market should be read. A billion-dollar total does not mean broad-based financing strength; it mostly means several companies raised very large rounds.
How much of the synthetic biology funding signal is driven by outliers?
As of July 2026, most of the funding signal in the synthetic biology market is driven by outliers. Over the past 12 months, rounds above $50M absorbed 79.2% of all disclosed capital.
Excluding rounds above $50M cuts total funding from $1.01B to $210.6M. That second number is a better proxy for ordinary company financing conditions in the synthetic biology market.
The average round size is $53.4M, but the median is only $19M. That gap shows that headline averages mostly describe the biggest rounds, not the typical financing environment.
Only 6 of 19 deals were $50M or larger, and only 3 were above $100M. The market has major capital depth for select winners, but most companies still raise much smaller rounds.
For more context on how outliers shape this space, see our deeper analysis of the synthetic biology market.
This chart, featured in our synthetic biology market deck, shows how Twist Bioscience is capturing share in synthetic biology
Is the synthetic biology market broad with many targets, or narrow with few fundable companies?
As of July 2026, the synthetic biology market looks narrow by visible funding activity. Over the past 12 months, the dataset includes only 19 disclosed deals and 19 unique companies.
The low deal count matters because synthetic biology is a broad scientific field. Public funding rounds, however, cluster around a small number of venture-backable themes.
The market is also narrow by frequency. A median of 1 deal per month means a few missing, undisclosed, or reclassified rounds could materially change deal-count conclusions.
That does not mean synthetic biology lacks activity. It means publicly disclosed venture financing is selective, especially when the dataset excludes conventional biotech, grant-heavy announcements, and traditional fermentation.
Is synthetic biology mostly an early-stage formation market or a late-stage scaling market?
As of July 2026, the synthetic biology market is early-stage by deal count but late-stage by capital. Over the past 12 months, Seed and Series A rounds account for 13 of 19 disclosed deals, while Series B and Series C rounds account for 70.7% of dollars.
Series A is the modal stage by activity. It produced 8 deals, or 42.1% of the dataset, which shows that new institutional validation is still happening.
Series C dominates capital despite being only 3 deals. Those rounds raised $509M, or 50.2% of total disclosed funding, mostly because NewLimit raised $435M.
Seed formation is visible but lightly funded. Seed rounds represent 26.3% of deals but only 3.5% of capital, suggesting new company formation is not being financed for expensive scale-up.
If you want to learn more about what investors are currently backing, check out our report on the synthetic biology market.
Which categories attract the most investor attention in synthetic biology?
As of July 2026, Synthetic Biology Therapeutics, Synbio Design Software, and Engineered Microbes attract the most investor attention by deal count. Over the past 12 months, each category produced 4 disclosed deals, or 21.1% of total activity.
The dollar picture is very different. Synthetic Biology Therapeutics raised $664.1M, or 65.5% of total capital, while Synbio Design Software raised $147.4M, or 14.5%.
Biofoundry Platforms raised $117.7M from 3 deals. That gives the category a meaningful middle-ground role between large therapeutic bets and smaller materials or food applications.
Synbio Materials Platforms had 3 deals but only $18.5M. That suggests investors are still cautious about commercialization timelines in materials, recycling, pigments, and consumer ingredient applications.
This chart, featured in our synthetic biology market deck, illustrates yearly funding for synthetic biology startups
Which categories attract disproportionately large checks in the synthetic biology market?
As of July 2026, Synthetic Biology Therapeutics attracts disproportionately large checks in the synthetic biology market. Over the past 12 months, the category captured 65.5% of capital from only 21.1% of deals, giving it a capital-share-to-deal-share ratio of 3.11x.
The therapeutic category also has the largest average deal size at $166M. NewLimit, Strand Therapeutics, Think Bioscience, and Telum Therapeutics all link synthetic biology to high-upside health applications.
Biofoundry Platforms is the next strongest category by average check size at $39.2M. Ansa Biotechnologies and bit.bio show that enabling infrastructure can still attract meaningful capital.
Synbio Materials Platforms has the weakest capital intensity in the dataset. It represents 15.8% of deals but only 1.8% of capital, which points to commercialization risk and smaller financing needs.
Which geographies matter most for fundraising in the synthetic biology market?
As of July 2026, North America matters most for synthetic biology fundraising by capital. Over the past 12 months, the region raised $849.4M, or 83.8% of all disclosed funding, from 8 deals.
Europe is competitive by deal count but not by check size. It produced 7 deals, close to North America’s 8, but raised only $121.6M.
Asia-Pacific appears mainly through biomanufacturing and ingredient infrastructure. Its 3 deals raised $27M combined, led by StrainX Bioworks and Cauldron Ferm.
The Middle East appears through one computational protein-design round. Scala Biodesign raised $16M, suggesting regional participation may start through software-enabled biology rather than large wet-lab manufacturing platforms.
If you want to identify where opportunities are currently emerging, explore our market pitch on synthetic biology.
Is the synthetic biology opportunity set broad or concentrated in one hub?
As of July 2026, the synthetic biology opportunity set is concentrated in a few hubs, not one single hub. Over the past 12 months, North America and Europe together captured 79% of disclosed deals and 95.8% of disclosed capital.
North America’s role is capital depth. It has only 42.1% of deals but 83.8% of funding, with an average round size of $106.2M.
Europe’s role is formation breadth. It has 36.8% of deals but only 12% of capital, with a median round size of $12M.
Latin America and Africa are absent from the qualifying disclosed dataset. That absence is more likely a funding, disclosure, and wet-lab infrastructure signal than proof that no synthetic biology work exists there.
This chart, featured in our synthetic biology market deck, compares the main business model options for synthetic biology platforms
Is synthetic biology a market of small experiments or scaled financings?
As of July 2026, the synthetic biology market contains both small experiments and scaled financings, but capital is mostly concentrated in scaled rounds. Over the past 12 months, 6 of 19 disclosed deals were $50M or larger.
The size distribution is split. Two deals were below $5M, 8 were between $5M and below $20M, 3 were between $20M and below $50M, and 6 were $50M or more.
The median deal size was $19M, which is a better proxy for the market’s center than the $53.4M average. The average is pulled up by NewLimit, Strand Therapeutics, and Profluent.
The market is therefore not only a small-check formation space. It is a market where ordinary financings remain constrained, while select companies can still raise $100M-plus rounds.
If you want to stay on top of the latest trends, risks, and opportunities in this market, check out our market report on synthetic biology, updated every quarter.
Who are the investors that appear the most in synthetic biology fundraising?
As of July 2026, repeat investors are rare in the synthetic biology market. Over the past 12 months, SOSV was the only clearly identifiable investor with more than one qualifying disclosed deal.
SOSV appeared in 3 disclosed qualifying rounds: Scindo, Cauldron Ferm, and Fermeate. That makes it the clearest repeat backer in the dataset.
No other investor was clearly identifiable in more than one qualifying disclosed deal from the public sources reviewed. This suggests the visible market is not dominated by one repeat syndicate.
One important caveat is that many round announcements do not disclose full investor lists or individual check sizes. So repeat-investor analysis is best read as a visibility signal, not a complete map of capital commitments.
This chart, featured in our synthetic biology market deck, illustrates the share of revenue generated by each customer segment in the synthetic biology market
INSIGHTS
The insights below come from reviewing every disclosed equity round in the synthetic biology market between August 2025 and July 2026. They are not row-by-row summaries. They are the reusable patterns that kept showing up across the 19-deal dataset, and they are meant to stay useful when reading any future synthetic biology funding announcement.
- The synthetic biology market’s capital signal is much stronger than its formation signal. Only 19 deals appeared, but they raised more than $1B. The market looks large because a few platform companies raised very large rounds.
- NewLimit changes the entire interpretation of the synthetic biology market. Without its $435M Series C, total disclosed funding falls from $1.01B to $579M. One company explains 42.9% of the period’s funding.
- The median round size is a better guide than the average. The median is $19M, while the average is $53.4M. That gap shows that headline averages mostly describe outliers.
- Synthetic Biology Therapeutics is not broader than other categories, but it is where investors write transformative checks. It has 21.1% of deals and 65.5% of capital. The category behaves more like high-upside venture biotech than ordinary synbio infrastructure.
- Synbio Design Software has a stronger breadth signal than a capital-intensity signal. It matches therapeutics with 4 deals, but its capital-share-to-deal-share ratio is only 0.69x. Software alone does not guarantee the largest checks.
- The strongest software-linked rounds connect computation to biological outputs. Profluent, Scala Biodesign, Scindo, and Pumpkinseed all turn AI or data into genome editors, proteins, enzymes, or proteomic datasets.
- Biofoundry Platforms show a middle-ground funding profile. They represent 15.8% of deals and 11.6% of capital. That suggests real validation, but not the same upside multiple as therapeutic platforms.
- Materials platforms are visible but undercapitalized. They produced 15.8% of deals but only 1.8% of capital. Investors still treat synbio materials as commercialization-risk-heavy.
- Food-oriented synthetic biology was the narrowest disclosed funding segment in this window. StrainX Bioworks was the only qualifying food-platform deal. That is much thinner than the broader precision-fermentation narrative suggests.
- Engineered biology for ingredients, agriculture, and fermentation economics is being funded mostly through smaller rounds. Engineered Microbes had 4 deals but only 5.3% of capital.
- The investable center of gravity is not “bio-based products.” It is platforms with venture-scale optionality. Therapeutics, programmable biology software, and biofoundry infrastructure collectively absorbed 91.6% of disclosed capital.
- Series A is the modal stage by deal count, with 8 of 19 deals. The synthetic biology market is still producing new institutional validation events, even though capital is concentrated later.
- Series C rounds dominate dollars despite being only 3 deals. They account for 50.2% of disclosed capital. Late-stage conviction is rare, but very large when it appears.
- Seed-stage company creation is alive but lightly funded. Seed accounts for 26.3% of deals and only 3.5% of capital. New formation is visible, but not broadly financed for expensive scale-up.
- The synthetic biology market has selective liquidity, not broad liquidity. The right company can still raise $100M-plus. Most qualifying rounds, however, remain below $20M.
- The top 3 deals account for 68.4% of total capital. Any market-growth conclusion should be stress-tested against the largest rounds before being treated as a broad trend.
- Excluding rounds above $50M cuts disclosed capital by 79.2%. That second view better reflects ordinary financing conditions for most synthetic biology companies.
- North America’s advantage is capital depth rather than only deal count. It has 42.1% of deals and 83.8% of capital. The region is where the largest platform checks are being written.
- Europe is competitive in formation but not in late-stage check size. It has 7 deals, close to North America’s 8, but only $121.6M compared with North America’s $849.4M.
- Asia-Pacific appears mainly through biomanufacturing and ingredient infrastructure. Its 3 deals total $27M, with no frontier therapeutic megadeal in the disclosed sample.
- The strongest non-therapeutic investment thesis is enablement, not end-product branding. DNA synthesis, protein design, fermentation infrastructure, and proteomic measurement look more fundable than consumer-facing biological products.
- Future synthetic biology funding claims should be evaluated in two passes. First, read the headline total with megadeals included. Then remove rounds above $50M to understand ordinary company financing conditions.
- Synthetic biology is too broad to be interpreted as one homogeneous market. Therapeutics behave like high-upside venture biotech, software behaves like enabling infrastructure, and materials or food behave like slower commercialization bets.
Business Wire (Strand Therapeutics), AgFunderNews (Scindo), Ansa Biotechnologies (Series B), Business Wire (Biocentis), Business Wire (Profluent), StartupTalky (Cellarim Labs), bit.bio (Series C), PR Newswire (Think Bioscience), EU-Startups (Octarine Bio), Antheia (Series C extension), AgFunderNews (baCta), Business Wire (Cauldron Ferm), EU-Startups (Epoch Biodesign), BioSpace (Scala Biodesign), Business Wire (Fermeate), Pumpkinseed (Series A), AgFunderNews (StrainX Bioworks), FinSMEs (NewLimit), Telum Therapeutics (Series A)
Related blog posts
- All the funding deals in the synthetic biology market
- The startups that have raised the most funding in synthetic biology
